Compounds > metformin
Page last updated: 2024-10-30

metformin and Carcinoma, Squamous Cell

metformin has been researched along with Carcinoma, Squamous Cell in 69 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)

Research Excerpts

ExcerptRelevanceReference
"5-Fluorouracil (5-FU) is a chemotherapeutic agent used to treat a variety of gastric cancers including oesophageal squamous cell carcinoma (OSCC), for which the 5-year mortality rate exceeds 85%."7.88Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB, 2018)
" A total of 184 patients had diabetes mellitus at the time of diagnosis, of whom 102 were taking metformin."7.83The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. ( Beadle, BM; Garden, AS; Lee, NY; Osborne, JR; Rivera, A; Skinner, HD; Spratt, DE; Zumsteg, ZS, 2016)
" We have previously shown that the anti-diabetic drug metformin is anti-proliferative and induces an intracellular reducing environment in oesophageal squamous cell carcinoma (OSCC) cell lines."7.81Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines. ( Birkhead, M; Damelin, LH; Jivan, R; Mavri-Damelin, D; Rousseau, AL; Veale, RB, 2015)
"In the present study, the ability of metformin to inhibit skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA) was analyzed in mice maintained on either an overweight control diet or an obesity-inducing diet."7.80Metformin inhibits skin tumor promotion in overweight and obese mice. ( Angel, JM; Beltran, L; Blando, J; Checkley, LA; Cho, J; DiGiovanni, J; Hursting, SD; Rho, O, 2014)
"Esophageal squamous cell carcinoma (ESCC) is an intractable digestive organ cancer and new treatment strategy is required."5.72Metformin-Induced Heat Shock Protein Family A Member 6 Is a Promising Biomarker of Esophageal Squamous Cell Carcinoma. ( Endo, S; Hirasawa, S; Iida, K; Kamata, T; Kano, M; Kinoshita, K; Kobayashi, S; Komatsu, A; Matsubara, H; Matsumoto, Y; Murakami, K; Okada, K; Otsuka, R; Ryuzaki, T; Sakata, H; Sasaki, T; Sekino, N; Shiraishi, T; Suito, H; Takahashi, M; Toyozumi, T; Yokoyama, M, 2022)
"Esophageal squamous cell carcinoma (ESCC) is an intractable digestive organ cancer that has proven difficult to treat despite multidisciplinary therapy, and a new treatment strategy is demanded."5.48Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma. ( Akimoto, AK; Akutsu, Y; Hanari, N; Hoshino, I; Iida, K; Kano, M; Matsubara, H; Matsumoto, Y; Murakami, K; Okada, K; Otsuka, R; Sakata, H; Sekino, N; Shiraishi, T; Takahashi, M; Toyozumi, T; Yokoyama, M, 2018)
"Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with poor prognosis in China."5.46Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin. ( Chi, Y; Ding, X; Fan, Q; Lv, Z; Shan, Z; Wang, F; Wang, J; Wang, L; Wang, T; Wu, S; Zhang, Y, 2017)
"A panel of 15 HNSCC cell lines was assayed for glucose and glutamine dependence and sensitivity to metabolic inhibitors."5.37Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. ( Davis-Malesevich, M; Fokt, I; Frederick, MJ; Myers, JN; Ow, TJ; Pickering, CR; Priebe, W; Sandulache, VC; Zhou, G, 2011)
"Metformin is proven to improve the prognosis of various cancers, but it is unknown if metformin could ameliorate hypopharyngeal cancer in diabetes mellitus patients."3.91The effect of metformin use on hypopharyngeal squamous cell carcinoma in diabetes mellitus patients. ( Chang, WD; Chen, CM; Chen, HL; Lu, JJ; Tsai, MH; Tsou, YA; Wu, TF, 2019)
"5-Fluorouracil (5-FU) is a chemotherapeutic agent used to treat a variety of gastric cancers including oesophageal squamous cell carcinoma (OSCC), for which the 5-year mortality rate exceeds 85%."3.88Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB, 2018)
" A total of 184 patients had diabetes mellitus at the time of diagnosis, of whom 102 were taking metformin."3.83The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. ( Beadle, BM; Garden, AS; Lee, NY; Osborne, JR; Rivera, A; Skinner, HD; Spratt, DE; Zumsteg, ZS, 2016)
" We have previously shown that the anti-diabetic drug metformin is anti-proliferative and induces an intracellular reducing environment in oesophageal squamous cell carcinoma (OSCC) cell lines."3.81Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines. ( Birkhead, M; Damelin, LH; Jivan, R; Mavri-Damelin, D; Rousseau, AL; Veale, RB, 2015)
"In the present study, the ability of metformin to inhibit skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA) was analyzed in mice maintained on either an overweight control diet or an obesity-inducing diet."3.80Metformin inhibits skin tumor promotion in overweight and obese mice. ( Angel, JM; Beltran, L; Blando, J; Checkley, LA; Cho, J; DiGiovanni, J; Hursting, SD; Rho, O, 2014)
"Metformin has been recognized as the first-line drug for the treatment of diabetes, and recent studies have shown that metformin has a remarkable suppressive effect on tumor progression."3.01Research Progress of Metformin in the Treatment of Oral Squamous Cell Carcinoma. ( Liu, J; Qiao, X; Zhao, J, 2023)
"Metformin was titrated to standard diabetic dose (2,000 mg/day) for a course of 9 or more days prior to surgery."2.84Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial. ( Birbe, R; Cognetti, D; Cotzia, P; Curry, J; Duddy, E; Gill, K; Johnson, J; Leiby, B; Lin, Z; Luginbuhl, A; Martinez-Outschoorn, U; Menezes, DW; Mollaee, M; Reyzer, M; Sprandio, J; Tassone, P; Tuluc, M; Vidal, MD; Zhan, T, 2017)
"Oral squamous cell carcinoma (OSCC) is considered as the sixth most common cancer worldwide characterized by high invasiveness, high metastasis rate and high mortality."1.91Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing. ( Chen, C; Ji, M; Li, X; Lv, Y; Ma, X; Qi, Y; Wang, Y; Xing, D; Xu, W; Zhang, J; Zhang, W; Zhao, J; Zhou, C, 2023)
"However, the role of IL-1RA in oral squamous cell carcinoma (OSCC), in particular the underlying mechanisms, remains to be elucidated."1.91IL-1RA promotes oral squamous cell carcinoma malignancy through mitochondrial metabolism-mediated EGFR/JNK/SOX2 pathway. ( Chan, LP; Chen, YK; Hu, SC; Hung, AC; Lo, S; Nguyen, HDH; Wang, YM; Wang, YY; Yuan, SF, 2023)
"Esophageal squamous cell carcinoma (ESCC) is an intractable digestive organ cancer and new treatment strategy is required."1.72Metformin-Induced Heat Shock Protein Family A Member 6 Is a Promising Biomarker of Esophageal Squamous Cell Carcinoma. ( Endo, S; Hirasawa, S; Iida, K; Kamata, T; Kano, M; Kinoshita, K; Kobayashi, S; Komatsu, A; Matsubara, H; Matsumoto, Y; Murakami, K; Okada, K; Otsuka, R; Ryuzaki, T; Sakata, H; Sasaki, T; Sekino, N; Shiraishi, T; Suito, H; Takahashi, M; Toyozumi, T; Yokoyama, M, 2022)
"The treatment with metformin caused a reduction in aerobic glycolysis and an increase in oxidative phosphorylation in 10GT sSCC cells."1.72Metformin overcomes metabolic reprogramming-induced resistance of skin squamous cell carcinoma to photodynamic therapy. ( Cuezva, JM; Gallego-Rentero, M; Gilaberte, Y; González, S; Juarranz, Á; Mascaraque-Checa, M; Nicolás-Morala, J; Portillo-Esnaola, M, 2022)
"Metformin increased HNSCC NK cell cytotoxicity and inhibited the CXCL1 pathway while stimulating the STAT1 pathway within HNSCC NK cells."1.72Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition. ( Borchers, M; Crago, A; Crist, M; Curry, J; Fuhrman, B; Gulati, S; Karivedu, V; Lehn, MA; Martinez-Outschoorn, U; Medvedovic, M; Palackdharry, S; Stone, T; Takiar, V; Wise-Draper, TM; Yaniv, B, 2022)
" Analyses of cumulative use showed a dose-response relationship in all patients, patients with adenocarcinoma and SCC, and with regional and metastatic LC."1.62Metformin use and lung cancer survival: a population-based study in Norway. ( Botteri, E; Brancher, S; Damhuis, RAM; Johannesen, TB; Strand, TE; Støer, NC; Weiderpass, E, 2021)
"To investigate the impact of type 2 diabetes mellitus (T2DM) and metformin treatment on the prognosis of oral squamous cell carcinoma (OSCC) patients received radical surgical treatment."1.56Metformin reduces the increased risk of oral squamous cell carcinoma recurrence in patients with type 2 diabetes mellitus: A cohort study with propensity score analyses. ( Chen, W; Hu, X; Huang, D; Huang, L; Mao, T; Shu, Y; Su, T; Wang, C; Wang, Z; Xia, K; Xiong, H; Yang, L; Yu, J, 2020)
"Metformin is an antidiabetic drug widely used for the treatment of type 2 diabetes."1.51Fibroblasts rescue oral squamous cancer cell from metformin-induced apoptosis via alleviating metabolic disbalance and inhibiting AMPK pathway. ( Bindoff, LA; Costea, DE; Fan, Y; Gao, Z; Li, L; Liang, X; Zhang, Z, 2019)
"Oral squamous cell carcinoma (OSCC) is the most common and aggressive epithelial tumor in the head and neck region with a rising incidence."1.51Metformin and 4SC-202 synergistically promote intrinsic cell apoptosis by accelerating ΔNp63 ubiquitination and degradation in oral squamous cell carcinoma. ( Cheng, B; Deng, M; Fan, Z; He, L; He, Y; Huang, Y; Ping, F; Tai, S; Xia, J; Zhang, C, 2019)
"Esophageal squamous cell carcinoma (ESCC) is an intractable digestive organ cancer that has proven difficult to treat despite multidisciplinary therapy, and a new treatment strategy is demanded."1.48Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma. ( Akimoto, AK; Akutsu, Y; Hanari, N; Hoshino, I; Iida, K; Kano, M; Matsubara, H; Matsumoto, Y; Murakami, K; Okada, K; Otsuka, R; Sakata, H; Sekino, N; Shiraishi, T; Takahashi, M; Toyozumi, T; Yokoyama, M, 2018)
"Metformin was administered orally to mice to test effects on immunohistochemical markers in xenografts."1.48Metformin Effects on Metabolic Coupling and Tumor Growth in Oral Cavity Squamous Cell Carcinoma Coinjection Xenografts. ( Curry, J; Domingo-Vidal, M; Lin, Z; Martinez-Outschoorn, U; Roche, M; Tassone, P; Tuluc, M; Whitaker-Menezes, D, 2018)
"Oesophageal squamous cell carcinoma (OSCC) is highly prevalent in developing countries but there has been little recent progress into efficacious yet affordable treatment strategies."1.48Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo. ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Peres, J; Prince, S; Veale, RB; Wadee, R, 2018)
"Metformin has been shown to protect against a variety of specific diseases, including cancer."1.46Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A. ( Chen, CH; Chien, CY; Chiu, TJ; Chuang, HC; Fang, FM; Huang, CC; Luo, SD; Shiu, LY; Su, LJ; Tsai, HT, 2017)
"Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with poor prognosis in China."1.46Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin. ( Chi, Y; Ding, X; Fan, Q; Lv, Z; Shan, Z; Wang, F; Wang, J; Wang, L; Wang, T; Wu, S; Zhang, Y, 2017)
"Patients included 1 with a history of oral cavity squamous cell carcinoma (SCC) and 2 with a history of laryngeal SCC."1.46Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients. ( Blitzer, A; Lerner, MZ; Mor, N; Paek, H; Strome, M, 2017)
"Metformin was reported to be effective against various cancers as it inhibits cell proliferation by activating AMPK, and inhibiting mTOR and HIF-1α."1.43Metformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma. ( Ferdous, T; Harada, K; Harada, T; Ueyama, Y, 2016)
"Metformin was administered in vitro to test the effect of Metformin under hypoxic conditions."1.43Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma. ( de Carvalho Fraga, CA; de Freitas Teles, L; de Jesus, SF; de Paula, AM; de Souza, MG; Farias, LC; Feltenberger, JD; Gomez, RS; Guimarães, AL; Guimarães, TA; Orsini, LA; Santos, ES; Santos, SH, 2016)
"Esophageal cancer is one of the most aggressive tumor types because of its invasiveness and metastatic potential."1.43Metformin inhibits the radiation-induced invasive phenotype of esophageal squamous cell carcinoma. ( Fushida, S; Harada, S; Hayashi, H; Kinoshita, J; Makino, I; Miyashita, T; Nakanuma, S; Nakayama, A; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Sakai, S; Tajima, H; Takamura, H; Tsukada, T, 2016)
"Most squamous cell carcinomas of the head and neck (HNSCC) exhibit a persistent activation of the PI3K-mTOR signaling pathway."1.42Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. ( Carey, TE; Ferris, RL; Gangane, N; Gutkind, JS; Komarck, CM; Madera, D; Martin, D; McHugh, JB; Molinolo, AA; Schneider, A; Seethala, RR; Vitale-Cross, L; Walline, HM; William, WN, 2015)
"Metformin is a biguanide widely prescribed as a first-line antidiabetic drug in type 2 diabetes mellitus patients."1.42Reduction behavior induced by HL010183, a metformin derivative against the growth of cutaneous squamous cell carcinoma. ( Guo, X; Liu, B; Liu, GJ; Miao, G; Zhang, X, 2015)
"Esophageal squamous cell carcinomas (ESCC) have become a severe threat to health and the current treatments for ESCC are frequently not effective."1.42Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo. ( Cai, X; Chen, C; Chen, X; Cheng, W; Guan, Y; Hu, X; Jing, X; Tan, X; Wang, Q, 2015)
"Metformin use has been associated with a dose-dependent increased response to neoadjuvant chemo(radio)therapy in esophageal cancer patients."1.42Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes. ( Anderegg, MC; Gisbertz, SS; Hulshof, MC; Lagarde, SM; Meijer, SL; Spierings, LE; van Berge Henegouwen, MI; van Laarhoven, HW; van Oijen, MG; Wilmink, JW, 2015)
"Metformin could inhibit the growth of OSCC cell line (HSC-3, HSC-4) by reducing cell proliferation and increasing cell apoptosis in vitro and in vivo."1.42[The inhibitory effect of metformin on oral squamous cell carcinoma]. ( Ji, N; Li, J; Wang, L; Wang, Z; Zhao, X; Zhou, Y, 2015)
"Metformin use has been linked to improved cancer outcomes."1.40Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma. ( Hamblin, JS; Kubik, MW; Myers, JN; Sandulache, VC; Skinner, HD; Zevallos, JP, 2014)
"Dasatinib is a Bcr-bl and Src kinase inhibitor that has potential against HNSCC."1.40Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. ( Chen, CC; Huang, LY; Huang, WC; Lin, YC; Lin, YT; Wei, TT; Wu, MH, 2014)
"Metformin is a commonly utilized antidiabetic agent, which has been associated with improved clinical outcomes in cancer patients."1.40Evaluating response to metformin/cisplatin combination in cancer cells via metabolic measurement and clonogenic survival. ( Sandulache, VC; Skinner, HD; Woo, SH; Yang, L, 2014)
"Metformin has been previously shown to reduce proliferative rates in various carcinoma cell lines."1.40Metformin induces an intracellular reductive state that protects oesophageal squamous cell carcinoma cells against cisplatin but not copper-bis(thiosemicarbazones). ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Rousseau, AL; Veale, RB, 2014)
"Metformin treatment led to a remarkable decrease of cyclin D1, cyclin-dependent kinase (CDK) 4 and CDK6 protein levels and phosphorylation of retinoblastoma protein, but did not affect p21 or p27 protein expression in OSCC cells."1.38In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. ( Chen, F; Hu, D; Hu, S; Luo, Q; Sun, Z; Yan, M, 2012)
"Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cancer in the world; the main risk factors are alcohol and tobacco use."1.38Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. ( Agarwal, C; Agarwal, R; Deep, G; Kaur, M; Sikka, A, 2012)
"Head and neck squamous cell carcinoma (HNSCC) is a major public health concern."1.38Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. ( Chen, W; Gutkind, JS; Martin, D; Maruyama, T; Molinolo, AA; Patel, V; Schneider, A; Vitale-Cross, L; Younis, RH, 2012)
"In the squamous cell carcinoma (SCC) cell lines SCC9 and SCC25, lovastatin treatment (1-25 µM, 24 hrs) induced LKB1 and AMPK activation similar to metformin (1-10 mM, 24 hrs), a known inducer of this pathway."1.38Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells. ( Dayekh, K; Dimitroulakos, J; Gorn-Hondermann, I; Ma, L; Niknejad, N, 2012)
"A panel of 15 HNSCC cell lines was assayed for glucose and glutamine dependence and sensitivity to metabolic inhibitors."1.37Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. ( Davis-Malesevich, M; Fokt, I; Frederick, MJ; Myers, JN; Ow, TJ; Pickering, CR; Priebe, W; Sandulache, VC; Zhou, G, 2011)
"Treatment with melatonin and metformin and their combinations was followed by significantly lower tumor multiplicity and smaller size, longer latency period and survival of tumor-bearers."1.36[Melatonin and metformin inhibit skin carcinogenesis induced by benz(a)pyrene in mice]. ( Anisimov, VN; Deriabina, ON; Plotnikova, NA, 2010)

Research

Studies (69)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's53 (76.81)24.3611
2020's16 (23.19)2.80

Authors

AuthorsStudies
Remenár, É1
Dóczi, R1
Dirner, A1
Sipos, A1
Perjési, A1
Tihanyi, D1
Vodicska, B1
Lakatos, D1
Horváth, K1
Kajáry, K1
Schwáb, R1
Déri, J1
Lengyel, CG1
Várkondi, E1
Vályi-Nagy, I1
Peták, I1
Sekino, N2
Kano, M2
Kobayashi, S1
Murakami, K3
Sakata, H2
Toyozumi, T3
Endo, S1
Matsumoto, Y2
Suito, H2
Takahashi, M3
Otsuka, R2
Yokoyama, M2
Shiraishi, T2
Okada, K2
Kamata, T1
Ryuzaki, T1
Hirasawa, S1
Kinoshita, K1
Sasaki, T1
Iida, K2
Komatsu, A1
Matsubara, H3
Nguyen, MT1
Choe, HC1
Kim, BH1
Ahn, SG1
Mascaraque-Checa, M1
Gallego-Rentero, M1
Nicolás-Morala, J1
Portillo-Esnaola, M1
Cuezva, JM1
González, S1
Gilaberte, Y1
Juarranz, Á1
Misitzis, A2
Stratigos, A1
Mastorakos, G2
Weinstock, M1
Lin, YC3
Chen, BS1
Crist, M1
Yaniv, B1
Palackdharry, S1
Lehn, MA1
Medvedovic, M1
Stone, T1
Gulati, S1
Karivedu, V1
Borchers, M1
Fuhrman, B1
Crago, A1
Curry, J3
Martinez-Outschoorn, U3
Takiar, V1
Wise-Draper, TM1
Ji, M2
Lv, Y2
Chen, C3
Xing, D2
Zhou, C2
Zhao, J4
Qi, Y3
Zhang, J5
Wang, Y6
Ma, X2
Xu, W4
Zhang, W2
Li, X13
Yuan, SF1
Wang, YM1
Chan, LP1
Hung, AC1
Nguyen, HDH1
Chen, YK1
Hu, SC1
Lo, S1
Wang, YY1
Liu, J1
Qiao, X1
Li, L2
Jiang, L1
Zhao, Y3
Zhang, XJ1
Wu, G2
Zhou, X3
Sun, J2
Bai, J1
Ren, B1
Tian, K1
Xu, Z2
Xiao, HL1
Zhou, Q1
Han, R1
Chen, H2
Wang, H3
Yang, Z1
Gao, C2
Cai, S1
He, Y4
Tsou, YA1
Chang, WD1
Lu, JJ1
Wu, TF1
Chen, HL1
Chen, CM1
Tsai, MH1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y4
Song, J5
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
Tong, F1
Dong, JH1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y2
Chen, Y4
Chen, L3
Shan, A1
Zhao, H2
Wu, M3
Ma, Q1
Wang, J5
Zhang, E1
Li, Y6
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X1
Ren, Y1
Li, J8
Li, P1
Jiao, Q1
Meng, P1
Wang, F3
Wang, YS1
Wang, C4
Wang, W1
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L3
Zhu, J2
Zhang, L2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Wang, X5
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y6
Wu, X1
Lu, J2
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Yang, X2
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S1
Zhang, M4
Zhang, H2
Yang, T2
Dong, Y2
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z2
Liang, C1
Yang, H1
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q3
Rathore, MG1
Reddy, K1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Lu, H1
Zhang, X5
Cai, X2
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y2
Chen, D2
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C1
Chen, W4
Hu, X4
Zhang, F2
Wei, H1
Wang, Z3
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J3
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y2
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D3
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W2
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X2
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F2
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X2
Duong, F1
Kong, W1
Chang, JH1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z2
Wang, T2
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G2
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J3
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P2
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z2
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Stratigos, AJ1
Beatson, M1
Dellavalle, RP1
Weinstock, MA1
Xiong, H1
Huang, L1
Mao, T2
Yang, L2
Huang, D1
Yu, J1
Shu, Y1
Xia, K1
Su, T2
Wei, J1
Zhong, D1
Brancher, S1
Støer, NC1
Weiderpass, E1
Damhuis, RAM1
Johannesen, TB1
Botteri, E1
Strand, TE1
Huang, DN1
Chen, WX1
Xiong, HF1
Ding, X1
Shan, Z1
Wu, S1
Chi, Y1
Lv, Z1
Fan, Q1
Chen, CH1
Tsai, HT1
Chuang, HC2
Shiu, LY1
Su, LJ1
Chiu, TJ1
Luo, SD1
Fang, FM1
Huang, CC1
Chien, CY1
Siddappa, G1
Kulsum, S1
Ravindra, DR1
Kumar, VV1
Raju, N1
Raghavan, N1
Sudheendra, HV1
Sharma, A1
Sunny, SP1
Jacob, T1
Kuruvilla, BT1
Benny, M1
Antony, B1
Seshadri, M2
Lakshminarayan, P1
Hicks, W1
Suresh, A1
Kuriakose, MA1
Mynhardt, C1
Damelin, LH4
Jivan, R4
Peres, J2
Prince, S2
Veale, RB4
Mavri-Damelin, D4
Sanada, Y1
Sasanuma, H1
Takeda, S1
Tano, K1
Masunaga, SI1
Tassone, P2
Domingo-Vidal, M1
Whitaker-Menezes, D1
Lin, Z2
Roche, M1
Tuluc, M2
Wadee, R1
Tyszka-Czochara, M1
Lasota, M1
Majka, M1
Akutsu, Y2
Hanari, N2
Hoshino, I2
Akimoto, AK1
Xu, T1
Qiao, M1
Verma, A1
Rich, LJ1
Vincent-Chong, VK1
Ogunsakin, A1
Infield, J1
Zuber, J1
Solomon, SS1
Lee, BB1
Kim, D1
Cho, EY1
Han, J1
Kim, HK1
Shim, YM1
Kim, DH1
Liu, CC1
Chou, KT1
Hsu, JW1
Lin, JH1
Hsu, TW1
Yen, DH1
Hung, SC1
Hsu, HS1
Zhang, Z1
Liang, X1
Bindoff, LA1
Costea, DE1
Tai, S1
Deng, M1
Fan, Z1
Ping, F1
He, L1
Zhang, C1
Cheng, B1
Xia, J1
Lee, DJ1
McMullen, CP1
Foreman, A1
Huang, SH1
Lu, L1
de Almeida, JR1
Liu, G1
Bratman, SV1
Goldstein, DP1
Sandulache, VC3
Hamblin, JS1
Skinner, HD4
Kubik, MW1
Myers, JN3
Zevallos, JP1
Ko, JC1
Chiu, HC1
Wo, TY1
Huang, YJ1
Tseng, SC1
Huang, YC1
Chen, HJ1
Syu, JJ1
Chen, CY1
Jian, YT1
Jian, YJ1
Lin, YW1
Checkley, LA1
Rho, O1
Angel, JM1
Blando, J1
Beltran, L1
Hursting, SD1
DiGiovanni, J1
Wu, MH1
Wei, TT1
Huang, WC1
Huang, LY1
Lin, YT1
Chen, CC1
Feng, Y1
Ke, C1
Tang, Q1
Dong, H1
Zheng, X1
Ke, J1
Yeung, SC1
Woo, SH2
Rousseau, AL2
Isozaki, Y1
Mori, M1
Nishimori, T1
Akanuma, N1
Takeshita, N1
Maruyama, T2
Suzuki, A1
Nakayama, T1
Madera, D1
Vitale-Cross, L2
Martin, D2
Schneider, A3
Molinolo, AA2
Gangane, N1
Carey, TE1
McHugh, JB1
Komarck, CM1
Walline, HM1
William, WN1
Seethala, RR1
Ferris, RL1
Gutkind, JS2
Miao, G1
Liu, B1
Guo, X1
Liu, GJ1
Kwon, M1
Roh, JL1
Lee, SW1
Kim, SB1
Choi, SH1
Nam, SY1
Birkhead, M1
Yang, LP1
Fitzgerald, A1
Lee, HY1
Pickering, C1
Van De Voorde, L1
Janssen, L1
Larue, R1
Houben, R1
Buijsen, J1
Sosef, M1
Vanneste, B1
Schraepen, MC1
Berbée, M1
Tan, X1
Cheng, W1
Guan, Y1
Jing, X1
Spierings, LE1
Lagarde, SM1
van Oijen, MG1
Gisbertz, SS1
Wilmink, JW1
Hulshof, MC1
Meijer, SL1
Anderegg, MC1
van Berge Henegouwen, MI1
van Laarhoven, HW1
Zhao, X1
Ji, N1
Zhou, Y1
Spratt, DE1
Beadle, BM1
Zumsteg, ZS1
Rivera, A1
Osborne, JR1
Garden, AS1
Lee, NY1
Yu, H1
Bian, X1
Gu, D1
Harada, K1
Ferdous, T1
Harada, T1
Ueyama, Y1
Guimarães, TA1
Farias, LC1
Santos, ES1
de Carvalho Fraga, CA1
Orsini, LA1
de Freitas Teles, L1
Feltenberger, JD1
de Jesus, SF1
de Souza, MG1
Santos, SH1
de Paula, AM1
Gomez, RS1
Guimarães, AL1
Nakayama, A1
Ninomiya, I1
Harada, S1
Tsukada, T1
Okamoto, K1
Nakanuma, S1
Sakai, S1
Makino, I1
Kinoshita, J1
Hayashi, H1
Oyama, K1
Miyashita, T1
Tajima, H1
Takamura, H1
Fushida, S1
Ohta, T1
Qi, X1
Xie, J1
Han, S1
Wei, Z1
Ni, Y1
Han, W1
Lerner, MZ1
Mor, N1
Paek, H1
Blitzer, A1
Strome, M1
Johnson, J1
Vidal, MD1
Menezes, DW1
Sprandio, J1
Mollaee, M1
Cotzia, P1
Birbe, R1
Gill, K1
Duddy, E1
Zhan, T1
Leiby, B1
Reyzer, M1
Cognetti, D1
Luginbuhl, A1
Yi, Y1
Ao, J1
Sun, S1
Bergholz, J1
Xiao, ZX1
Deriabina, ON1
Plotnikova, NA1
Anisimov, VN1
Vazquez-Martin, A1
Oliveras-Ferraros, C1
Cufí, S1
Martin-Castillo, B1
Menendez, JA1
Ow, TJ1
Pickering, CR1
Frederick, MJ1
Fokt, I1
Davis-Malesevich, M1
Priebe, W1
Sikka, A1
Kaur, M1
Agarwal, C1
Deep, G1
Agarwal, R1
Younis, RH2
Patel, V1
Patel, H1
Ord, RA1
Basile, JR1
Ma, L1
Niknejad, N1
Gorn-Hondermann, I1
Dayekh, K1
Dimitroulakos, J1
Luo, Q1
Hu, D1
Hu, S1
Yan, M1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling.[NCT02083692]Early Phase 150 participants (Actual)Interventional2013-09-30Completed
A Phase I Dose-finding Study of Metformin in Combination With Concurrent Cisplatin and Radiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma[NCT02325401]Phase 120 participants (Actual)Interventional2015-05-11Completed
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial[NCT00847912]Phase 4954 participants (Actual)Interventional2009-06-26Completed
Pilot Study of Metformin (MF) IN HNSCC (Head and Neck Squamous Cell Carcinoma) as Window Trial Design in Operable HNSCC, to Investigate the Effects of MF, Tumor Genotype and MF Genotype Interactions, on Tumor Metabolism and Anoikis[NCT02402348]Early Phase 13 participants (Actual)Interventional2014-12-31Terminated (stopped due to Funding not available, PI left institution)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Maximum Tolerated Dose (MTD) of Metformin in Combination With Concurrent Cisplatin and Radiation

Cohorts of patients received escalating doses of metformin (2000 mg, 2550 mg, or 3000 mg divided into daily doses) with a 7-day to 14-day lead-in prior to CRT based on the modified toxicity probability interval design to allow for possible re-escalation after previous de-escalation and to maximize the ability to identify the maximum tolerated dose (MTD). Patients continued to receive metformin for the duration of CRT as tolerated. (NCT02325401)
Timeframe: 24 months

Interventionmg (Number)
Metformin (2000mg) With ChemoradiationNA
Metformin (2550mg) With ChemoradiationNA
Metformin (3000mg) With ChemoradiationNA

Number of Participants Experiencing No-Reoccurrence at 36 Months

Patients were evaulated at 36 months to determine if there was recurrence of disease. (NCT02325401)
Timeframe: 36 months

InterventionParticipants (Count of Participants)
Metformin (2000mg) With Chemoradiation6
Metformin (2550mg) With Chemoradiation8
Metformin (3000mg) With Chemoradiation4

Number of Participants With Adverse Events

Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.Any participants with any adverse event at any grade was included. Adverse events were collected during the on study period of 21 weeks up to three months after the study for a total of 34 weeks. (NCT02325401)
Timeframe: 36 months

InterventionParticipants (Count of Participants)
Metformin (2000mg) With Chemoradiation6
Metformin (2550mg) With Chemoradiation7
Metformin (3000mg) With Chemoradiation4

Overall Survival

2 year overall survival (NCT02325401)
Timeframe: 24 months

Interventionparticipants (Number)
Metformin (2000mg) With Chemoradiation5
Metformin (2550mg) With Chemoradiation8
Metformin (3000mg) With Chemoradiation4

Progression Free Survival

2-year progression free survival (NCT02325401)
Timeframe: 24 months

InterventionParticipants (Count of Participants)
Metformin (2000mg) With Chemoradiation6
Metformin (2550mg) With Chemoradiation8
Metformin (3000mg) With Chemoradiation4

Hazard Ratio for Surgically Treated KC

(NCT00847912)
Timeframe: date of randomization to last visit before end of study follow up (6/30/2013), assessed up to four years

Interventionparticipants (Number)
Arm 1: 5-fluorouracil182
Arm 2: Placebo, Vehicle Control177

The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed

Diagnosis of the first Primary Basil Cell Carcinoma (BCC) or primary Squamous Cell Carcinoma (SCC) on the face or ears that was removed surgically. (NCT00847912)
Timeframe: From randomization to last visit prior to end of study date (6/30/2013), assessed up to four years

Interventionyears (Median)
Arm 1: 5-fluorouracil3.37
Arm 2: Placebo, Vehicle Control3.52

Reviews

2 reviews available for metformin and Carcinoma, Squamous Cell

ArticleYear
Research Progress of Metformin in the Treatment of Oral Squamous Cell Carcinoma.
    Endocrinology, 2023, 09-23, Volume: 164, Issue:11

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Met

2023
Research Progress of Metformin in the Treatment of Oral Squamous Cell Carcinoma.
    Endocrinology, 2023, 09-23, Volume: 164, Issue:11

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Met

2023
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021

Trials

4 trials available for metformin and Carcinoma, Squamous Cell

ArticleYear
Antidiabetic Treatment in Patients at High Risk for a Subsequent Keratinocyte Carcinoma.
    Journal of drugs in dermatology : JDD, 2022, May-01, Volume: 21, Issue:5

    Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Diabetes Mellitus, Type 2; Female; Humans; Hy

2022
Antidiabetic Treatment in Patients at High Risk for a Subsequent Keratinocyte Carcinoma.
    Journal of drugs in dermatology : JDD, 2022, May-01, Volume: 21, Issue:5

    Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Diabetes Mellitus, Type 2; Female; Humans; Hy

2022
Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 12-01, Volume: 25, Issue:23

    Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-

2019
Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 12-01, Volume: 25, Issue:23

    Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-

2019
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial.
    The Laryngoscope, 2017, Volume: 127, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; M

2017
Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial.
    The Laryngoscope, 2017, Volume: 127, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; M

2017

Other Studies

64 other studies available for metformin and Carcinoma, Squamous Cell

ArticleYear
Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With
    JCO precision oncology, 2022, Volume: 6

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Drug

2022
Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With
    JCO precision oncology, 2022, Volume: 6

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Drug

2022
Metformin-Induced Heat Shock Protein Family A Member 6 Is a Promising Biomarker of Esophageal Squamous Cell Carcinoma.
    Oncology, 2022, Volume: 100, Issue:5

    Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Esophageal Neoplasms; Esophageal Squa

2022
Metformin-Induced Heat Shock Protein Family A Member 6 Is a Promising Biomarker of Esophageal Squamous Cell Carcinoma.
    Oncology, 2022, Volume: 100, Issue:5

    Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Esophageal Neoplasms; Esophageal Squa

2022
A new link between apoptosis induced by the metformin derivative HL156A and autophagy in oral squamous cell carcinoma.
    European journal of pharmacology, 2022, Apr-05, Volume: 920

    Topics: Animals; Apoptosis; Autophagy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Guani

2022
A new link between apoptosis induced by the metformin derivative HL156A and autophagy in oral squamous cell carcinoma.
    European journal of pharmacology, 2022, Apr-05, Volume: 920

    Topics: Animals; Apoptosis; Autophagy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Guani

2022
Metformin overcomes metabolic reprogramming-induced resistance of skin squamous cell carcinoma to photodynamic therapy.
    Molecular metabolism, 2022, Volume: 60

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Humans; Metformin; Mice;

2022
Metformin overcomes metabolic reprogramming-induced resistance of skin squamous cell carcinoma to photodynamic therapy.
    Molecular metabolism, 2022, Volume: 60

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Humans; Metformin; Mice;

2022
Identifying Drug Targets of Oral Squamous Cell Carcinoma through a Systems Biology Method and Genome-Wide Microarray Data for Drug Discovery by Deep Learning and Drug Design Specifications.
    International journal of molecular sciences, 2022, Sep-08, Volume: 23, Issue:18

    Topics: Biomarkers; Biomarkers, Tumor; Carcinoma, Squamous Cell; Deep Learning; Drug Design; Drug Discovery;

2022
Identifying Drug Targets of Oral Squamous Cell Carcinoma through a Systems Biology Method and Genome-Wide Microarray Data for Drug Discovery by Deep Learning and Drug Design Specifications.
    International journal of molecular sciences, 2022, Sep-08, Volume: 23, Issue:18

    Topics: Biomarkers; Biomarkers, Tumor; Carcinoma, Squamous Cell; Deep Learning; Drug Design; Drug Discovery;

2022
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:11

    Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells,

2022
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:11

    Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells,

2022
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:11

    Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells,

2022
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:11

    Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells,

2022
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:11

    Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells,

2022
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:11

    Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells,

2022
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:11

    Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells,

2022
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:11

    Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells,

2022
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
    Life sciences, 2023, Feb-15, Volume: 315

    Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation;

2023
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
    Life sciences, 2023, Feb-15, Volume: 315

    Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation;

2023
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
    Life sciences, 2023, Feb-15, Volume: 315

    Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation;

2023
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
    Life sciences, 2023, Feb-15, Volume: 315

    Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation;

2023
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
    Life sciences, 2023, Feb-15, Volume: 315

    Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation;

2023
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
    Life sciences, 2023, Feb-15, Volume: 315

    Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation;

2023
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
    Life sciences, 2023, Feb-15, Volume: 315

    Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation;

2023
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
    Life sciences, 2023, Feb-15, Volume: 315

    Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation;

2023
IL-1RA promotes oral squamous cell carcinoma malignancy through mitochondrial metabolism-mediated EGFR/JNK/SOX2 pathway.
    Journal of translational medicine, 2023, 07-17, Volume: 21, Issue:1

    Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; D

2023
IL-1RA promotes oral squamous cell carcinoma malignancy through mitochondrial metabolism-mediated EGFR/JNK/SOX2 pathway.
    Journal of translational medicine, 2023, 07-17, Volume: 21, Issue:1

    Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; D

2023
The effect of metformin use on hypopharyngeal squamous cell carcinoma in diabetes mellitus patients.
    BMC cancer, 2019, Aug-30, Volume: 19, Issue:1

    Topics: Aged; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Diabetes Mellitus, Type 2;

2019
The effect of metformin use on hypopharyngeal squamous cell carcinoma in diabetes mellitus patients.
    BMC cancer, 2019, Aug-30, Volume: 19, Issue:1

    Topics: Aged; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Diabetes Mellitus, Type 2;

2019
The association of metformin use with keratinocyte carcinoma development in high-risk patients.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Keratinocytes; Metformin; Skin Neoplasms

2020
The association of metformin use with keratinocyte carcinoma development in high-risk patients.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Keratinocytes; Metformin; Skin Neoplasms

2020
Metformin reduces the increased risk of oral squamous cell carcinoma recurrence in patients with type 2 diabetes mellitus: A cohort study with propensity score analyses.
    Surgical oncology, 2020, Volume: 35

    Topics: Carcinoma, Squamous Cell; China; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypog

2020
Metformin reduces the increased risk of oral squamous cell carcinoma recurrence in patients with type 2 diabetes mellitus: A cohort study with propensity score analyses.
    Surgical oncology, 2020, Volume: 35

    Topics: Carcinoma, Squamous Cell; China; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypog

2020
Metformin inhibits proliferation of oral squamous cell carcinoma cells by suppressing proteolysis of nerve growth factor receptor.
    Archives of oral biology, 2021, Volume: 121

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Met

2021
Metformin inhibits proliferation of oral squamous cell carcinoma cells by suppressing proteolysis of nerve growth factor receptor.
    Archives of oral biology, 2021, Volume: 121

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Met

2021
Metformin use and lung cancer survival: a population-based study in Norway.
    British journal of cancer, 2021, Volume: 124, Issue:5

    Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lu

2021
Metformin use and lung cancer survival: a population-based study in Norway.
    British journal of cancer, 2021, Volume: 124, Issue:5

    Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lu

2021
[Preliminary clinical study on the effect of metformin on prognosis of patients with oral squamous cell carcinoma after surgical treatment].
    Shanghai kou qiang yi xue = Shanghai journal of stomatology, 2021, Volume: 30, Issue:1

    Topics: Carcinoma, Squamous Cell; Humans; Male; Metformin; Mouth Neoplasms; Prognosis; Squamous Cell Carcino

2021
[Preliminary clinical study on the effect of metformin on prognosis of patients with oral squamous cell carcinoma after surgical treatment].
    Shanghai kou qiang yi xue = Shanghai journal of stomatology, 2021, Volume: 30, Issue:1

    Topics: Carcinoma, Squamous Cell; Humans; Male; Metformin; Mouth Neoplasms; Prognosis; Squamous Cell Carcino

2021
Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin.
    PloS one, 2017, Volume: 12, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prol

2017
Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin.
    PloS one, 2017, Volume: 12, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prol

2017
Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A.
    Scientific reports, 2017, 05-02, Volume: 7, Issue:1

    Topics: Antineoplastic Agents; Aurora Kinase A; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; D

2017
Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A.
    Scientific reports, 2017, 05-02, Volume: 7, Issue:1

    Topics: Antineoplastic Agents; Aurora Kinase A; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; D

2017
Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells.
    Molecular carcinogenesis, 2017, Volume: 56, Issue:11

    Topics: 4-Nitroquinoline-1-oxide; AC133 Antigen; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; C

2017
Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells.
    Molecular carcinogenesis, 2017, Volume: 56, Issue:11

    Topics: 4-Nitroquinoline-1-oxide; AC133 Antigen; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; C

2017
Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma.
    Journal of cellular biochemistry, 2018, Volume: 119, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor;

2018
Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma.
    Journal of cellular biochemistry, 2018, Volume: 119, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor;

2018
Disruption of Hif-1α enhances cytotoxic effects of metformin in murine squamous cell carcinoma.
    International journal of radiation biology, 2018, Volume: 94, Issue:1

    Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Hypoxia-Inducible Factor 1, alph

2018
Disruption of Hif-1α enhances cytotoxic effects of metformin in murine squamous cell carcinoma.
    International journal of radiation biology, 2018, Volume: 94, Issue:1

    Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Hypoxia-Inducible Factor 1, alph

2018
Metformin Effects on Metabolic Coupling and Tumor Growth in Oral Cavity Squamous Cell Carcinoma Coinjection Xenografts.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2018, Volume: 158, Issue:5

    Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Caveolin 1; Cell Culture Techniques; Disease Models, A

2018
Metformin Effects on Metabolic Coupling and Tumor Growth in Oral Cavity Squamous Cell Carcinoma Coinjection Xenografts.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2018, Volume: 158, Issue:5

    Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Caveolin 1; Cell Culture Techniques; Disease Models, A

2018
Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo.
    Cancer letters, 2018, 03-28, Volume: 417

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Squamous Cell; Cell L

2018
Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo.
    Cancer letters, 2018, 03-28, Volume: 417

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Squamous Cell; Cell L

2018
Caffeic Acid and Metformin Inhibit Invasive Phenotype Induced by TGF-β1 in C-4I and HTB-35/SiHa Human Cervical Squamous Carcinoma Cells by Acting on Different Molecular Targets.
    International journal of molecular sciences, 2018, Jan-16, Volume: 19, Issue:1

    Topics: Biomarkers, Tumor; Caffeic Acids; Carbonic Anhydrase IX; Carcinoma, Squamous Cell; Cell Adhesion; Ce

2018
Caffeic Acid and Metformin Inhibit Invasive Phenotype Induced by TGF-β1 in C-4I and HTB-35/SiHa Human Cervical Squamous Carcinoma Cells by Acting on Different Molecular Targets.
    International journal of molecular sciences, 2018, Jan-16, Volume: 19, Issue:1

    Topics: Biomarkers, Tumor; Caffeic Acids; Carbonic Anhydrase IX; Carcinoma, Squamous Cell; Cell Adhesion; Ce

2018
Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma.
    Cancer science, 2018, Volume: 109, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Ce

2018
Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma.
    Cancer science, 2018, Volume: 109, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Ce

2018
Prognostic value of metformin for non-small cell lung cancer patients with diabetes.
    World journal of surgical oncology, 2018, Mar-20, Volume: 16, Issue:1

    Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diabetes Mellitus, Type 2; Female; F

2018
Prognostic value of metformin for non-small cell lung cancer patients with diabetes.
    World journal of surgical oncology, 2018, Mar-20, Volume: 16, Issue:1

    Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diabetes Mellitus, Type 2; Female; F

2018
Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2018, Volume: 47, Issue:5

    Topics: Animals; Carcinoma, Squamous Cell; Cell Proliferation; Female; Head and Neck Neoplasms; Hemoglobins;

2018
Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2018, Volume: 47, Issue:5

    Topics: Animals; Carcinoma, Squamous Cell; Cell Proliferation; Female; Head and Neck Neoplasms; Hemoglobins;

2018
Metformin Associated With Improved Outcomes in Diabetic Patients With Laryngeal and Oropharyngeal Carcinoma.
    The American journal of the medical sciences, 2018, Volume: 356, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Diabetes Mellitus; Hospitals, Veterans; Hypoglycemi

2018
Metformin Associated With Improved Outcomes in Diabetic Patients With Laryngeal and Oropharyngeal Carcinoma.
    The American journal of the medical sciences, 2018, Volume: 356, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Diabetes Mellitus; Hospitals, Veterans; Hypoglycemi

2018
Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells.
    Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:4

    Topics: Acetylation; Adenocarcinoma of Lung; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Ap

2019
Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells.
    Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:4

    Topics: Acetylation; Adenocarcinoma of Lung; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Ap

2019
High metabolic rate and stem cell characteristics of esophageal cancer stem-like cells depend on the Hsp27-AKT-HK2 pathway.
    International journal of cancer, 2019, 10-15, Volume: 145, Issue:8

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Deoxyglucose; Esophageal Neoplasms; Gene Expression Regu

2019
High metabolic rate and stem cell characteristics of esophageal cancer stem-like cells depend on the Hsp27-AKT-HK2 pathway.
    International journal of cancer, 2019, 10-15, Volume: 145, Issue:8

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Deoxyglucose; Esophageal Neoplasms; Gene Expression Regu

2019
Fibroblasts rescue oral squamous cancer cell from metformin-induced apoptosis via alleviating metabolic disbalance and inhibiting AMPK pathway.
    Cell cycle (Georgetown, Tex.), 2019, Volume: 18, Issue:9

    Topics: AMP-Activated Protein Kinases; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Cell Surviva

2019
Fibroblasts rescue oral squamous cancer cell from metformin-induced apoptosis via alleviating metabolic disbalance and inhibiting AMPK pathway.
    Cell cycle (Georgetown, Tex.), 2019, Volume: 18, Issue:9

    Topics: AMP-Activated Protein Kinases; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Cell Surviva

2019
Metformin and 4SC-202 synergistically promote intrinsic cell apoptosis by accelerating ΔNp63 ubiquitination and degradation in oral squamous cell carcinoma.
    Cancer medicine, 2019, Volume: 8, Issue:7

    Topics: Animals; Apoptosis; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell

2019
Metformin and 4SC-202 synergistically promote intrinsic cell apoptosis by accelerating ΔNp63 ubiquitination and degradation in oral squamous cell carcinoma.
    Cancer medicine, 2019, Volume: 8, Issue:7

    Topics: Animals; Apoptosis; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell

2019
Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort study.
    Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale, 2019, Jul-25, Volume: 48, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Diabetes Mellitus, Type 2; Female; Head an

2019
Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort study.
    Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale, 2019, Jul-25, Volume: 48, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Diabetes Mellitus, Type 2; Female; Head an

2019
Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma.
    Head & neck, 2014, Volume: 36, Issue:7

    Topics: Aged; Carcinoma, Squamous Cell; Diabetes Mellitus; Disease-Free Survival; Follow-Up Studies; Humans;

2014
Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma.
    Head & neck, 2014, Volume: 36, Issue:7

    Topics: Aged; Carcinoma, Squamous Cell; Diabetes Mellitus; Disease-Free Survival; Follow-Up Studies; Humans;

2014
Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells.
    Lung cancer (Amsterdam, Netherlands), 2013, Volume: 82, Issue:3

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvan

2013
Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells.
    Lung cancer (Amsterdam, Netherlands), 2013, Volume: 82, Issue:3

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvan

2013
Metformin inhibits skin tumor promotion in overweight and obese mice.
    Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:1

    Topics: Adenylate Kinase; Adiponectin; Animals; Body Weight; Carcinogenesis; Carcinoma, Squamous Cell; Diet;

2014
Metformin inhibits skin tumor promotion in overweight and obese mice.
    Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:1

    Topics: Adenylate Kinase; Adiponectin; Animals; Body Weight; Carcinogenesis; Carcinoma, Squamous Cell; Diet;

2014
Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.
    Oncotarget, 2014, Jan-15, Volume: 5, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; C

2014
Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.
    Oncotarget, 2014, Jan-15, Volume: 5, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; C

2014
Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling.
    Cell death & disease, 2014, Feb-27, Volume: 5

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Squa

2014
Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling.
    Cell death & disease, 2014, Feb-27, Volume: 5

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Squa

2014
Evaluating response to metformin/cisplatin combination in cancer cells via metabolic measurement and clonogenic survival.
    Methods in molecular biology (Clifton, N.J.), 2014, Volume: 1165

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cel

2014
Evaluating response to metformin/cisplatin combination in cancer cells via metabolic measurement and clonogenic survival.
    Methods in molecular biology (Clifton, N.J.), 2014, Volume: 1165

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cel

2014
Metformin induces an intracellular reductive state that protects oesophageal squamous cell carcinoma cells against cisplatin but not copper-bis(thiosemicarbazones).
    BMC cancer, 2014, May-05, Volume: 14

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Prol

2014
Metformin induces an intracellular reductive state that protects oesophageal squamous cell carcinoma cells against cisplatin but not copper-bis(thiosemicarbazones).
    BMC cancer, 2014, May-05, Volume: 14

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Prol

2014
Screening of alternative drugs to the tumor suppressor miR-375 in esophageal squamous cell carcinoma using the connectivity map.
    Oncology, 2014, Volume: 87, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Benzocaine; Betazole; Carcinoma, Squamous Cell; Catechin; Cell Lin

2014
Screening of alternative drugs to the tumor suppressor miR-375 in esophageal squamous cell carcinoma using the connectivity map.
    Oncology, 2014, Volume: 87, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Benzocaine; Betazole; Carcinoma, Squamous Cell; Catechin; Cell Lin

2014
Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
    Cancer prevention research (Philadelphia, Pa.), 2015, Volume: 8, Issue:3

    Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Case-Control Studies; Cell Cycle; C

2015
Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
    Cancer prevention research (Philadelphia, Pa.), 2015, Volume: 8, Issue:3

    Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Case-Control Studies; Cell Cycle; C

2015
Reduction behavior induced by HL010183, a metformin derivative against the growth of cutaneous squamous cell carcinoma.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Femal

2015
Reduction behavior induced by HL010183, a metformin derivative against the growth of cutaneous squamous cell carcinoma.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Femal

2015
Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival.
    The oncologist, 2015, Volume: 20, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Diabetes Mellitus; Female; Head and Neck N

2015
Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival.
    The oncologist, 2015, Volume: 20, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Diabetes Mellitus; Female; Head and Neck N

2015
Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines.
    Journal of cellular biochemistry, 2015, Volume: 116, Issue:10

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Copper; Disulfiram; Drug Synergism;

2015
Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines.
    Journal of cellular biochemistry, 2015, Volume: 116, Issue:10

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Copper; Disulfiram; Drug Synergism;

2015
Down-regulation of malic enzyme 1 and 2: Sensitizing head and neck squamous cell carcinoma cells to therapy-induced senescence.
    Head & neck, 2016, Volume: 38 Suppl 1

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p

2016
Down-regulation of malic enzyme 1 and 2: Sensitizing head and neck squamous cell carcinoma cells to therapy-induced senescence.
    Head & neck, 2016, Volume: 38 Suppl 1

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p

2016
Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2015
Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2015
Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: AMP-Activated Protein Kinases; Animals; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumo

2015
Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: AMP-Activated Protein Kinases; Animals; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumo

2015
Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes.
    Annals of surgical oncology, 2015, Volume: 22 Suppl 3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2015
Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes.
    Annals of surgical oncology, 2015, Volume: 22 Suppl 3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2015
[The inhibitory effect of metformin on oral squamous cell carcinoma].
    Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, 2015, Volume: 50, Issue:6

    Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Flow

2015
[The inhibitory effect of metformin on oral squamous cell carcinoma].
    Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, 2015, Volume: 50, Issue:6

    Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Flow

2015
The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study.
    International journal of radiation oncology, biology, physics, 2016, Mar-01, Volume: 94, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Carcinoma, Squamous Cell; Diabetes Mellitus; D

2016
The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study.
    International journal of radiation oncology, biology, physics, 2016, Mar-01, Volume: 94, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Carcinoma, Squamous Cell; Diabetes Mellitus; D

2016
Metformin Synergistically Enhances Cisplatin-Induced Cytotoxicity in Esophageal Squamous Cancer Cells under Glucose-Deprivation Conditions.
    BioMed research international, 2016, Volume: 2016

    Topics: AMP-Activated Protein Kinases; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prolifera

2016
Metformin Synergistically Enhances Cisplatin-Induced Cytotoxicity in Esophageal Squamous Cancer Cells under Glucose-Deprivation Conditions.
    BioMed research international, 2016, Volume: 2016

    Topics: AMP-Activated Protein Kinases; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prolifera

2016
Metformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma.
    International journal of oncology, 2016, Volume: 49, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Dru

2016
Metformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma.
    International journal of oncology, 2016, Volume: 49, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Dru

2016
Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma.
    Oncotarget, 2016, Aug-23, Volume: 7, Issue:34

    Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Death; Cell Hypoxia; Cell Line; Cell Line, Tumor; Cell Mov

2016
Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma.
    Oncotarget, 2016, Aug-23, Volume: 7, Issue:34

    Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Death; Cell Hypoxia; Cell Line; Cell Line, Tumor; Cell Mov

2016
Metformin inhibits the radiation-induced invasive phenotype of esophageal squamous cell carcinoma.
    International journal of oncology, 2016, Volume: 49, Issue:5

    Topics: Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Adhesion; Cell Movement; Cell Prolifera

2016
Metformin inhibits the radiation-induced invasive phenotype of esophageal squamous cell carcinoma.
    International journal of oncology, 2016, Volume: 49, Issue:5

    Topics: Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Adhesion; Cell Movement; Cell Prolifera

2016
Metformin sensitizes the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-κB/HIF-1α signal axis.
    Scientific reports, 2016, 10-20, Volume: 6

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Disease Model

2016
Metformin sensitizes the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-κB/HIF-1α signal axis.
    Scientific reports, 2016, 10-20, Volume: 6

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Disease Model

2016
Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients.
    The Annals of otology, rhinology, and laryngology, 2017, Volume: 126, Issue:4

    Topics: Aged; Carcinoma, Squamous Cell; Disease Progression; Female; Glottis; Head and Neck Neoplasms; Human

2017
Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients.
    The Annals of otology, rhinology, and laryngology, 2017, Volume: 126, Issue:4

    Topics: Aged; Carcinoma, Squamous Cell; Disease Progression; Female; Glottis; Head and Neck Neoplasms; Human

2017
Metformin Promotes AMP-activated Protein Kinase-independent Suppression of ΔNp63α Protein Expression and Inhibits Cancer Cell Viability.
    The Journal of biological chemistry, 2017, Mar-31, Volume: 292, Issue:13

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line,

2017
Metformin Promotes AMP-activated Protein Kinase-independent Suppression of ΔNp63α Protein Expression and Inhibits Cancer Cell Viability.
    The Journal of biological chemistry, 2017, Mar-31, Volume: 292, Issue:13

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line,

2017
[Melatonin and metformin inhibit skin carcinogenesis induced by benz(a)pyrene in mice].
    Voprosy onkologii, 2010, Volume: 56, Issue:5

    Topics: Animals; Anticarcinogenic Agents; Antioxidants; Carcinoma, Squamous Cell; Catalase; Central Nervous

2010
[Melatonin and metformin inhibit skin carcinogenesis induced by benz(a)pyrene in mice].
    Voprosy onkologii, 2010, Volume: 56, Issue:5

    Topics: Animals; Anticarcinogenic Agents; Antioxidants; Carcinoma, Squamous Cell; Catalase; Central Nervous

2010
Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response.
    Cell cycle (Georgetown, Tex.), 2011, May-01, Volume: 10, Issue:9

    Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tu

2011
Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response.
    Cell cycle (Georgetown, Tex.), 2011, May-01, Volume: 10, Issue:9

    Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tu

2011
Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.
    Cancer, 2011, Jul-01, Volume: 117, Issue:13

    Topics: Adenosine Triphosphate; Carcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Prol

2011
Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.
    Cancer, 2011, Jul-01, Volume: 117, Issue:13

    Topics: Adenosine Triphosphate; Carcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Prol

2011
Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation.
    Cell cycle (Georgetown, Tex.), 2012, Apr-01, Volume: 11, Issue:7

    Topics: beta-Transducin Repeat-Containing Proteins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prolife

2012
Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation.
    Cell cycle (Georgetown, Tex.), 2012, Apr-01, Volume: 11, Issue:7

    Topics: beta-Transducin Repeat-Containing Proteins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prolife

2012
Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions.
    Cancer prevention research (Philadelphia, Pa.), 2012, Volume: 5, Issue:4

    Topics: AMP-Activated Protein Kinases; Animals; Anticarcinogenic Agents; Carcinogens; Carcinoma, Squamous Ce

2012
Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions.
    Cancer prevention research (Philadelphia, Pa.), 2012, Volume: 5, Issue:4

    Topics: AMP-Activated Protein Kinases; Animals; Anticarcinogenic Agents; Carcinogens; Carcinoma, Squamous Ce

2012
Differential expression of organic cation transporter OCT-3 in oral premalignant and malignant lesions: potential implications in the antineoplastic effects of metformin.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2013, Volume: 42, Issue:3

    Topics: AMP-Activated Protein Kinases; Anticarcinogenic Agents; Blotting, Western; Carcinoma, Squamous Cell;

2013
Differential expression of organic cation transporter OCT-3 in oral premalignant and malignant lesions: potential implications in the antineoplastic effects of metformin.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2013, Volume: 42, Issue:3

    Topics: AMP-Activated Protein Kinases; Anticarcinogenic Agents; Blotting, Western; Carcinoma, Squamous Cell;

2013
Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells.
    PloS one, 2012, Volume: 7, Issue:9

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents;

2012
Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells.
    PloS one, 2012, Volume: 7, Issue:9

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents;

2012
In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma.
    BMC cancer, 2012, Nov-14, Volume: 12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Li

2012
In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma.
    BMC cancer, 2012, Nov-14, Volume: 12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Li

2012